The takeaway
Sagimet Biosciences Inc. Series A Common Stock shows a pronounced seasonal pattern over 3 years of data — strongest in October (+11.7%) and softest in February (−29.5%).
Right now
In July, the stock has risen 67% of years, averaging +4.8%, about +2.7 pts better than the S&P 500.
The full picture
Sagimet Biosciences Inc. Series A Common Stock's most dependable month has been October, higher in 2 of 3 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+41.9 pts); it has trailed the market most in February (−29.2 pts).
“vs S&P” is Sagimet Biosciences Inc. Series A Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Sagimet Biosciences Inc. Series A Common Stock’s own seasonal edge from broad market drift.
Reality check
Over the last 3 years, October has closed higher 67% of the time versus 67% across the last 3 years — the pattern is holding.
Figures are the typical (median) October return and how often it rose — the last 3 years versus the last 3(the heatmap’s default window). This verdict stays anchored to that 3-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The year leans October's way without overwhelming the rest of it: the stock has closed higher in 2 of 3 Octobers, its most dependable month if not a dominant one.
Its average (+11.7%) and median (+22.1%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even October ranges by 48.3% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: October has cleared the S&P 500 by +10.7 points above the index. That consistency sets it apart from the field, where the average stock manages October only about 53% of the time.
A few other months pull their weight: July and November have also closed higher more often than not. The weaker half of the year is plainer: February has been the soft spot — the weakest of 4 months that average a loss (−29.5%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, August, and September.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 3-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (October), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2023 its best month (October, +11.7%) has run well ahead of its worst (February, −29.5%) — the heatmap above shows how steady that gap has been year to year.
October has been the strongest, averaging +11.7% and closing higher in 2 of 3 years since 2023.
It's the weakest, averaging −29.5% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade